ADMA - ADMA Biologics shares rise on Q1 earnings beat

ADMA Biologics (ADMA) shares rise more than 5% during post-market trading after the company reported first-quarter results that beat Wall Street estimates, helped by the continued commercial ramp of its IVIG product portfolio.The company's total revenue in the quarter grew 57% to $16.01M, beating analysts' estimate by $1.43M.ADMA said that it expects 2021 to be a strong year of growth, and added that the company remains on track to deliver on several strategic and financial objectives over the near term.Consolidated net loss for the quarter ended March 31 was $18.4M, or $(0.16) per share, compared to a consolidated net loss of $19.2M, or $(0.26) per share, last year.At March 31, 2021, ADMA had cash and cash equivalents of about $62M and accounts receivable of $15.4M, compared to cash and cash equivalents of $55.9M and accounts receivable of $13.2M as of December 31, 2020.Previously (May 12): ADMA Biologics EPS beats by $0.01, beats on revenue.

For further details see:

ADMA Biologics shares rise on Q1 earnings beat